Literature DB >> 17108194

Fetal DNA in maternal plasma: progress through epigenetics.

Y M Dennis Lo1.   

Abstract

The discovery of cell-free fetal DNA in maternal plasma has opened up new possibilities for noninvasive prenatal diagnosis. Most of the work in this field has focused on the detection of fetal genetic markers that are distinguishable from the background maternal DNA. The feasibility of detecting fetal epigenetic markers in maternal plasma using an imprinted locus was demonstrated in 2002. This work has recently led to the development of the first universal fetal epigenetic marker, hypomethylated maspin, which can be used for fetal DNA detection in maternal plasma, irrespective of fetal gender and genetic polymorphisms. It is expected that many more fetal epigenetic markers that can be used in this manner will be developed over the next few years. These markers may catalyze the eventual clinical use of circulating fetal DNA for noninvasive prenatal diagnosis, such as for the detection of fetal chromosomal aneuploidies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108194     DOI: 10.1196/annals.1368.009

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Evaluation of extraction methods for methylated cell-free fetal DNA from maternal plasma.

Authors:  Ji Hyae Lim; Bom Yi Lee; Jin Woo Kim; You Jung Han; Jin Hoon Chung; Min Hyoung Kim; Dong Wook Kwak; So Yeon Park; Hee Back Choi; Hyun Mee Ryu
Journal:  J Assist Reprod Genet       Date:  2018-02-08       Impact factor: 3.412

2.  Prenatal RhD Testing: A Review of Studies Published from 2006 to 2008.

Authors:  Tobias Jörg Legler; Sina Patricia Müller; Alexander Haverkamp; Simon Grill; Sinuhe Hahn
Journal:  Transfus Med Hemother       Date:  2009-05-14       Impact factor: 3.747

3.  Epigenetic influences in the aetiology of cancers arising from breast and prostate: a hypothesised transgenerational evolution in chromatin accessibility.

Authors:  Francis L Martin
Journal:  ISRN Oncol       Date:  2013-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.